Bank of New York Mellon Corp Has $26.53 Million Position in Krystal Biotech, Inc. (NASDAQ:KRYS)

Bank of New York Mellon Corp lessened its position in Krystal Biotech, Inc. (NASDAQ:KRYS) by 1.3% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 169,346 shares of the company’s stock after selling 2,307 shares during the quarter. Bank of New York Mellon Corp owned approximately 0.59% of Krystal Biotech worth $26,530,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently bought and sold shares of the company. Segall Bryant & Hamill LLC raised its stake in shares of Krystal Biotech by 352.4% during the 3rd quarter. Segall Bryant & Hamill LLC now owns 157,144 shares of the company’s stock worth $28,605,000 after purchasing an additional 122,407 shares in the last quarter. State Street Corp increased its holdings in Krystal Biotech by 9.0% during the third quarter. State Street Corp now owns 1,452,811 shares of the company’s stock worth $264,455,000 after buying an additional 119,936 shares during the last quarter. Franklin Resources Inc. raised its position in Krystal Biotech by 34.2% during the third quarter. Franklin Resources Inc. now owns 243,760 shares of the company’s stock worth $43,774,000 after acquiring an additional 62,178 shares in the last quarter. Braidwell LP lifted its stake in Krystal Biotech by 57.4% in the third quarter. Braidwell LP now owns 168,691 shares of the company’s stock valued at $30,707,000 after acquiring an additional 61,512 shares during the last quarter. Finally, TimesSquare Capital Management LLC grew its position in shares of Krystal Biotech by 39.1% in the 4th quarter. TimesSquare Capital Management LLC now owns 158,868 shares of the company’s stock valued at $24,888,000 after acquiring an additional 44,646 shares during the period. Institutional investors own 86.29% of the company’s stock.

Krystal Biotech Trading Up 0.6 %

Shares of NASDAQ KRYS opened at $179.93 on Monday. The firm has a market cap of $5.18 billion, a P/E ratio of 60.18 and a beta of 0.87. The business’s 50 day moving average is $161.18 and its 200-day moving average is $174.38. Krystal Biotech, Inc. has a 1-year low of $141.72 and a 1-year high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings data on Monday, February 24th. The company reported $1.52 earnings per share for the quarter, topping the consensus estimate of $1.29 by $0.23. The firm had revenue of $91.10 million for the quarter, compared to analysts’ expectations of $91.35 million. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The company’s quarterly revenue was up 116.4% compared to the same quarter last year. During the same quarter last year, the business earned $0.30 EPS. Analysts forecast that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

Insiders Place Their Bets

In other news, CAO Kathryn Romano sold 750 shares of the firm’s stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $175.22, for a total transaction of $131,415.00. Following the transaction, the chief accounting officer now directly owns 12,604 shares of the company’s stock, valued at approximately $2,208,472.88. This trade represents a 5.62 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $164.78, for a total value of $4,119,500.00. Following the completion of the sale, the insider now owns 1,475,882 shares of the company’s stock, valued at approximately $243,195,835.96. This trade represents a 1.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 14.10% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on KRYS shares. Chardan Capital upped their target price on shares of Krystal Biotech from $212.00 to $218.00 and gave the company a “buy” rating in a report on Thursday, February 20th. Citigroup boosted their price target on Krystal Biotech from $206.00 to $215.00 and gave the stock a “neutral” rating in a research report on Thursday, February 20th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 price objective on shares of Krystal Biotech in a research report on Thursday, February 20th. HC Wainwright reissued a “buy” rating and set a $221.00 target price on shares of Krystal Biotech in a report on Friday, February 28th. Finally, Jefferies Financial Group started coverage on Krystal Biotech in a research note on Wednesday, March 5th. They issued a “buy” rating and a $245.00 price target on the stock. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $220.00.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).